496 results match your criteria ClinicoEconomics and Outcomes Research [Journal]


Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab.

Clinicoecon Outcomes Res 2019 15;11:99-110. Epub 2019 Jan 15.

Real World Value and Evidence, Janssen Scientific Affairs, LLC, Horsham, PA, USA.

Purpose: The objectives of this study were to evaluate and compare treatment patterns and infusion-related health care resource expenditures for rheumatoid arthritis (RA) patients initiating golimumab for intravenous use (GLM-IV) and infliximab (IFX) therapy and to assess cost implications from the commercial perspective.

Methods: Adult RA patients with a new episode of GLM-IV or IFX treatment between Janu-ary 1, 2014 and March 31, 2016 were identified from MarketScan databases and evaluated for maintenance infusion intervals and related costs of treatment. IFX and GLM-IV patients were matched 1:1 on index medication treatment duration, gender, payer type, prior biologic use, and post-index methotrexate use. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/comparative-analysis-of-us-real-wo
Publisher Site
http://dx.doi.org/10.2147/CEOR.S185547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338107PMC
January 2019
2 Reads

Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review.

Clinicoecon Outcomes Res 2019 14;11:87-98. Epub 2019 Jan 14.

Pfizer Inc, Collegeville, PA, USA.

Background: AML is a rapidly progressing bone marrow cancer, with poor survival rates compared to other types of leukemia. IC and NIC as well as BSC treatment options are available; however, there is scant published literature on the impact of disease and treatment on the HRQoL in patients receiving NIC.

Aim: This study determined the HRQoL among NIC AML patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S187409DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336133PMC
January 2019
1 Read

Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands.

Clinicoecon Outcomes Res 2019 14;11:73-82. Epub 2019 Jan 14.

Leiden University Medical Center, Leiden, the Netherlands.

Aim: The aim of this study was to perform a cost-effectiveness analysis to establish the cost-effectiveness of sensor-augmented pump therapy (SAP) with automated insulin suspension vs continuous subcutaneous insulin infusion (CSII) alone in patients with type 1 diabetes in the Netherlands.

Patients And Methods: The analysis was performed using the IQVIA CORE Diabetes Model (CDM) in two different patient cohorts: one with suboptimal glycemic control at baseline (mean age 27 years, mean baseline HbA1c 8.0% [64 mmol/mol]) and the other at increased risk of hypoglycemic events (mean age 18. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S186298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336135PMC
January 2019

Health-related outcomes, health care resource utilization, and costs of multiple sclerosis in Japan compared with US and five EU countries.

Clinicoecon Outcomes Res 2019 7;11:61-71. Epub 2019 Jan 7.

Global Outcomes and Epidemiology Research. Data Sciences Institute, Takeda Pharmaceutical International, Cambridge, MA 02139, USA.

Purpose: Multiple sclerosis (MS) imposes a huge burden on patients. This study examined the relationship between MS and health-related and economic burden in Japan; secondarily, health status was compared across patients with MS in Japan, US, and five European Union (5EU) countries (France, Germany, Italy, Spain, and UK).

Methods: A retrospective cross-sectional study was conducted using self-reported data from 2009 to 2014 Japan National Health and Wellness Survey (n=145,759). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S179903DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327901PMC
January 2019
3 Reads

Impact of migraine on health care utilization and expenses in obese adults: a US population-based study.

Clinicoecon Outcomes Res 2019 31;11:51-59. Epub 2018 Dec 31.

Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA.

Purpose: Migraine prevalence increases in people with obesity, and obesity may contribute to migraine chronicity. Yet, few studies examine the effect of comorbid migraine on health care utilization and expenses in obese US adults. This study aimed to identify risk factors for migraine and compare the use of health care services and expenses between migraineurs and non-migraineurs in obese US adults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S189699DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318707PMC
December 2018
1 Read

Systematic literature review of treatment patterns for venous thromboembolism patients during transitions from inpatient to post-discharge settings.

Clinicoecon Outcomes Res 2019 19;11:23-49. Epub 2018 Dec 19.

US Medical Affairs, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Introduction: Direct oral anticoagulants (DOACs) have emerged as viable alternatives to traditional treatments such as vitamin K antagonists (VKAs) for venous thromboembolism (VTE). The objective of this review was to summarize evidence on the use of DOACs and VKAs to treat VTE in the US for patients transitioning from inpatient to post-discharge settings.

Materials And Methods: A systematic review of the VTE literature identified studies published in English (January 1, 2011-December 31, 2016) that reported inpatient and post-discharge treatments and discharge location. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S179080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305128PMC
December 2018
1 Read

Indirect costs associated with premature mortality among those with veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan dysfunction post-hematopoietic stem-cell-transplant.

Clinicoecon Outcomes Res 2019 17;11:13-22. Epub 2018 Dec 17.

Health Economics and Outcomes Research, Jazz Pharmaceuticals, Palo Alto, CA, USA,

Purpose: The study objective was to develop an economic model to assess projected costs of lost productivity associated with premature deaths due to veno-occlusive disease (VOD)/ sinusoidal obstruction syndrome (SOS) with multiorgan dysfunction (MOD) among patients in the US who underwent hematopoietic stem-cell transplant (HSCT) in 2013.

Methods: Data sources included the US Census Bureau and Department of Health, epidemiologic research organizations, and medical research literature. The model considered only lost productivity associated with premature death, with lifetime salary assumed to reflect productivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S184883DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301294PMC
December 2018
2 Reads

A US hospital budget impact analysis of a skin closure system compared with standard of care in hip and knee arthroplasty.

Clinicoecon Outcomes Res 2019 17;11:1-11. Epub 2018 Dec 17.

Cornerstone Research Group Inc., Burlington, ON, Canada,

Background: Medicare's mandatory bundle for hip and knee arthroplasty necessitates provider accountability for quality and cost of care to 90 days, and wound closure may be a key area of consideration. The DERMABOND PRINEO Skin Closure System (22 cm) combines a topical skin adhesive with a self-adhering mesh without the need for dressing changes or suture or staple removal. This study estimated the budget impact of the Skin Closure System compared to other wound closure methods for hip and knee arthroplasty. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S181630DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301301PMC
December 2018
2 Reads

The number needed to treat and relevant between-trial comparisons of competing interventions.

Clinicoecon Outcomes Res 2018 14;10:865-871. Epub 2018 Dec 14.

Evidence and Value Generation, Takeda International, Deerfield, IL, USA,

The number needed to treat (NNT) is considered an intuitive as well as popular effect measure. The aims of this review were to 1) explain why we cannot compare trial-specific NNT estimates for the competing treatments evaluated in different randomized controlled trials (RCTs) and 2) outline the principles of how relative treatment effects of different trials can be compared and results can be presented as NNT, without violating the principles of valid between-trial comparisons. Our premise is that ratio measures for relative treatment effects of response outcomes are less prone to effect modification than absolute difference measures of response outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S180491DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298880PMC
December 2018
3 Reads

The cost impact to Medicare of shifting treatment of worsening heart failure from inpatient to outpatient management settings.

Clinicoecon Outcomes Res 2018 14;10:855-863. Epub 2018 Dec 14.

MedStar Washington Hospital Center, Washington, DC, USA.

Purpose: The aim of this study was to quantify the potential cost savings to Medicare of shifting the site of treatment for worsening heart failure (HF) from inpatient to outpatient (OP) settings for a subset of worsening HF episodes among the Medicare fee-for-service (FFS) population.

Materials And Methods: A cross-sectional analysis of a random 5% sample of 2014 FFS Medicare beneficiaries was conducted. Incidence and cost of worsening HF episodes in both inpatient and OP settings were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S184048DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298883PMC
December 2018
1 Read

A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions.

Clinicoecon Outcomes Res 2018 26;10:821-854. Epub 2018 Nov 26.

Department of Health Research Methods, Evidence and Impact (HEI), McMaster University, Hamilton, ON, Canada,

Introduction: Budget impact analysis (BIA) in health care, sometimes referred to as resource impact, is the financial change in the use of health resources associated with adding a new drug to a formulary or the adoption of a new health technology. Several national and transnational organizations worldwide have updated their BIA guidelines in the past 4 years. The aim of the present review was to provide a comprehensive list of the key recommendations of BIA guidelines from different countries that may be of interest for those who wish to build or to update BIA guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S178825DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263295PMC
November 2018
1 Read

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies.

Clinicoecon Outcomes Res 2018 16;10:805-819. Epub 2018 Nov 16.

Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA,

Objective: To estimate the 5-year budget impact (BI) on a US health plan of introducing sarilumab - a human immunoglobulin G1 anti-IL-6 receptor α monoclonal antibody - as combination treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or monotherapy in patients with moderate-to-severe rheumatoid arthritis (RA).

Methods: BI analysis was conducted from a commercial payer perspective. Treatment-eligible populations included adult patients with moderate-to-severe RA and inadequate response (IR) to csDMARDs or tumor necrosis factor (TNF)-α inhibitors-IR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S163829DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247948PMC
November 2018
2 Reads

Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective.

Clinicoecon Outcomes Res 2018 14;10:791-803. Epub 2018 Nov 14.

HEOR & Data Analytics, Novo Nordisk Inc, Plainsboro, NJ, USA,

Background: The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcomes Results (LEADER) clinical trial demonstrated that liraglutide added to standard-of-care (SoC) therapy for type 2 diabetes (T2D) with established cardiovascular disease (CVD) or elevated cardiovascular (CV) risk was associated with lower rates of death from CVD, nonfatal myocardial infarction (MI), or nonfatal stroke than SoC alone.

Objective: The objective of this study was to assess the cost-effectiveness (CE) and budget impact of liraglutide vs SoC in T2D patients with established CVD or elevated CV risk, over a lifetime horizon from a US managed care perspective.

Methods: A cohort state-transition model (costs and benefits discounted at 3% per year) was used to predict diabetes-related complications and death (CV and all-cause). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S180067DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241540PMC
November 2018
1 Read

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain.

Clinicoecon Outcomes Res 2018 14;10:773-790. Epub 2018 Nov 14.

Oblikue Consulting, Barcelona, Spain,

Purpose: The aim of this study was to evaluate the cost-effectiveness of ribociclib compared to palbociclib, both in combination with letrozole, in the first-line treatment of postmenopausal women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (ABC) from the perspective of the Spanish National Health System (NHS).

Patients And Methods: Disease progression was simulated with a partitioned survival model developed from the parameterization and extrapolation of survival curves of postmenopausal women with HR+/HER2- ABC from clinical trials with ribociclib or palbociclib, both in combination with letrozole. The model was structured on the basis of three health states (progression-free, progressed disease, and death), with a 1-month cycle length and inclusion of subsequent treatments administered for disease progression, over a time horizon of 15 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S178934DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241542PMC
November 2018
2 Reads

Impact of postcolectomy adhesion-related complications on healthcare utilization.

Clinicoecon Outcomes Res 2018 14;10:761-771. Epub 2018 Nov 14.

Medical Devices-Epidemiology, Johnson and Johnson, New Brunswick, NJ 08901, USA,

Objective: The objective of this study was to explore adhesion-related complications (ARCs) within 1 year after colectomy.

Methods: Using Truven MarketScan® Commercial and Medicare databases, the first inpatient colectomies during 2009-2013 (index) were identified: left, right, partial, transverse, or total. One-year continuous enrollment was required pre and postindex. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S167741DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241541PMC
November 2018
3 Reads

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain.

Clinicoecon Outcomes Res 2018 12;10:747-759. Epub 2018 Nov 12.

Global Patient Outcomes and Real World Evidence International, Eli Lilly, Surrey, UK.

Background: Currently, several biologic agents are available for the treatment of moderate-to-severe plaque psoriasis, including newer agents with similar mechanisms of action and efficacy; therefore, there is a need to evaluate their efficiency in terms of cost effectiveness.

Objective: This study evaluates the cost effectiveness of recently approved interleukin (IL)-17A antagonists, ixekizumab and secukinumab, for the treatment of moderate-to-severe plaque psoriasis from the perspective of the Spanish National Health System (NHS).

Materials And Methods: A Markov model with a lifetime horizon was developed to compare the cost effectiveness of ixekizumab vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S167727DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237133PMC
November 2018
4 Reads

Cost-utility of surgical sutureless bioprostheses vs TAVI in aortic valve replacement for patients at intermediate and high surgical risk.

Clinicoecon Outcomes Res 2018 8;10:733-745. Epub 2018 Nov 8.

Minimally Invasive Cardiothoracic Department, Istituto Clinico Sant'Ambrogio, Gruppo Ospedaliero San Donato, Milan, Italy.

Background: Meta-analyses of studies comparing transcatheter aortic valve implants (TAVIs) and sutureless aortic valve replacement (SU-AVR) show differing effectiveness and safety profiles. The approaches also differ in their surgical cost (including operating room and device).

Objective: The objective of this study was to assess the incremental cost-utility of SU-AVR vs TAVIs for the treatment of intermediate- to high-risk patients in the US, Germany, France, Italy, UK, and Australia. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/cost-utility-of-surgical-sutureles
Publisher Site
http://dx.doi.org/10.2147/CEOR.S185743DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231515PMC
November 2018
11 Reads

Erratum: Impact of comorbidity on the risk and cost of hospitalization in HIV-infected patients: real-world data from Abruzzo Region [Corrigendum].

Authors:

Clinicoecon Outcomes Res 2018 8;10:731. Epub 2018 Nov 8.

[This corrects the article on p. 389 in vol. 10, PMID: 30087571. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S188625DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231512PMC
November 2018
9 Reads

Economic analysis of pharmacist-administered influenza vaccines in Ontario, Canada.

Clinicoecon Outcomes Res 2018 24;10:655-663. Epub 2018 Oct 24.

School of Pharmacy, Faculty of Science, University of Waterloo, Waterloo, ON, Canada.

Objective: The aim of this study was to evaluate the impact of pharmacist administration of influenza vaccine in Ontario on: 1) vaccination-associated costs related to the number of people vaccinated; 2) annual influenza-related outcomes and costs; and 3) change in productivity costs.

Methods: Using available data for Ontario, the total number of vaccinations given by providers in the 2011/12 influenza season (pre) was compared to the 2013/14 influenza season (post). Vaccine costs and provider fees for administration were assigned for both periods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S167500DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207261PMC
October 2018
4 Reads

Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon.

Clinicoecon Outcomes Res 2018 2;10:723-730. Epub 2018 Nov 2.

Value and Access, Biogen, Cambridge, MA, USA,

Background: Real-world outcomes from staying on an interferon beta (IFNβ) vs switching to another IFNβ could help guide treatment decisions. This study's objective was to compare outcomes of stable multiple sclerosis (MS) patients on an IFNβ who stayed on therapy vs those who switched to another IFNβ.

Methods: MS patients were identified from the Optum Insights Clinformatics Data Mart Multi-Plan who were 18-64 years old and relapse-free (stable) over 1 year while continuously being treated with an IFNβ. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S163907DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219109PMC
November 2018
8 Reads

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia.

Clinicoecon Outcomes Res 2018 5;10:715-721. Epub 2018 Nov 5.

Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, Scotland, UK.

Background: Immune thrombocytopenia (ITP) is an auto-immune disorder characterized by enhanced platelet destruction and, subsequently, the potential for increased bleeding. Thrombopoietin receptor (TPO-R) agonists have recently emerged as promising therapies for ITP patients who are refractory to other treatments. While eltrombopag (EPAG) is the only TPO-R agonist US Food and Drug Administration approved for use in pediatric patients, romiplostin (ROMI) has been used in Phase III clinical studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S177338DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223346PMC
November 2018
8 Reads

Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia.

Clinicoecon Outcomes Res 2018 1;10:705-713. Epub 2018 Nov 1.

William R. Lindsay Chair of Health Economics, University of Glasgow, Glasgow, Scotland, UK.

Background: Thrombopoietin-receptor agonists eltrombopag (EPAG) and romiplostim (ROMI) are treatment options for adults with chronic immune thrombocytopenia (cITP) who have had an insufficient response to corticosteroids or immunoglobulins.

Methods: A cost-consequence model was developed to evaluate the costs relative to treatment success of EPAG, ROMI, and watch and rescue (W&R) in previously treated patients. The primary endpoint assessed was severe bleeding, derived from all identified phase III registered clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S177324DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219311PMC
November 2018
8 Reads

Incremental health care resource utilization and expenditures associated with autosomal-dominant polycystic kidney disease.

Clinicoecon Outcomes Res 2018 31;10:693-703. Epub 2018 Oct 31.

Regenstrief Center for Healthcare Engineering and Center for Health Outcomes Research and Policy, College of Pharmacy, Purdue University, West Lafayette, IN, USA,

Purpose: Incremental health care resource utilization and expenditures associated with autosomal dominant polycystic kidney disease (ADPKD) were estimated.

Methods: Study data were from a large administrative claims database. Individuals aged 18 years or older enrolled in tracked health plans for 12 months from April 1, 2011 through March 31, 2012, and with an International Classification of Disease, Ninth Revision, Clinical Modification diagnosis code for "polycystic kidney, autosomal dominant" (753. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S167837DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216970PMC
October 2018
15 Reads

Burden of cancer pain in developing countries: a narrative literature review.

Clinicoecon Outcomes Res 2018 2;10:675-691. Epub 2018 Nov 2.

Mundipharma Pte Ltd., Singapore, Singapore,

Cancer pain is one of the most common, feared, debilitating, and often undertreated symptoms among cancer patients. It needs attention since it has a significant impact on the quality of life (QoL) of the patients. Also, since cancer has emerged as a major health problem in developing countries, there is a need to strengthen preventive strategies for effective cancer pain management and provide comfort to cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S181192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219110PMC
November 2018
10 Reads

Economic benefits of implementing patient-centered medical home among patients with hypertension.

Clinicoecon Outcomes Res 2018 31;10:665-673. Epub 2018 Oct 31.

Department of Clinical Pharmacy, College of Pharmacy, Qassim University, Buraydah, Qassim, Saudi Arabia.

Introduction: Despite the strong evidence of an association between adoption of the patient-centered medical home (PCMH) and improved clinical outcomes among patients with hypertension, evidence for associations between the PCMH and health care utilization and cost reduction within the general adult population with hypertension is less developed.

Objective: This study was designed to examine the effect of PCMH on health service expenditures and utilization in a national sample of the US adult population who were diagnosed with hypertension.

Methods: The 2010-2015 Medical Expenditure Panel Survey data were used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S179337DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216964PMC
October 2018
19 Reads

Health-related outcomes and economic burden in Japan: focus on inflammatory bowel disease, multiple sclerosis, and depression.

Authors:
Kaoru Yamabe

Clinicoecon Outcomes Res 2018 23;10:653-654. Epub 2018 Oct 23.

Healthcare Policy and Access, Takeda Pharmaceutical Company Limited, Chuou-ku, Tokyo, Japan,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S184289DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203106PMC
October 2018
2 Reads

Impact of antiepileptic-drug treatment burden on health-care-resource utilization and costs.

Clinicoecon Outcomes Res 2018 16;10:619-627. Epub 2018 Oct 16.

RTI Health Solutions, Research Triangle Park, NC 27709, USA.

Background: Complex titration requirements and dosing of antiepileptic drugs (AEDs) may pose a significant treatment burden for patients with epilepsy. This study evaluated health-care-resource utilization (HCRU) rates and costs by treatment burden, defined as number of daily pills and dosing frequency, among managed-care enrollees with epilepsy who initiated AED monotherapy.

Methods: This retrospective longitudinal study examined administrative HC-claim data in patients aged ≥18 years with two or more pharmacy claims for an AED and two or more medical claims for epilepsy or afebrile convulsion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S180913DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201987PMC
October 2018
9 Reads

Sacroiliac joint fusion health care cost comparison prior to and following surgery: an administrative claims analysis.

Clinicoecon Outcomes Res 2018 17;10:643-651. Epub 2018 Oct 17.

Department of Orthopedic Surgery, University of Minnesota, Minneapolis, MN, USA.

Purpose: To assess real-world expenditures on surgical and non-surgical treatment for sacroiliac joint (SIJ) pain by comparing direct health care costs before and after surgery in patients who underwent an SIJ fusion (SIJF) procedure.

Materials And Methods: This retrospective observational study examined administrative claims data (January 1, 2010 to February 28, 2017) for adult commercial health plan members with a medical claim for SIJF. Identified patients were included if they had continuous enrollment in the health plan for 12 months pre-SIJF (baseline period) and 12 months post-SIJF (follow-up period). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S177094DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198879PMC
October 2018
2 Reads

Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure.

Clinicoecon Outcomes Res 2018 17;10:629-641. Epub 2018 Oct 17.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Purpose: The purpose of this study was to evaluate the economic burden of frontline failure (FLF) among classical Hodgkin lymphoma (HL) patients during and after treatment.

Patients And Methods: The population consisted of adult HL patients identified from January 2010 through September 2015 without any other primary cancer prior to HL diagnosis, who also had a frontline (FL) regimen indicative of curative intent. Patients were characterized as FLF (those who restart, switch to any chemotherapy; had a hematopoietic stem cell transplant; or newly initiated radiation therapy [RT] after discontinuing FL) or non-FLF (those not considered as FLF). Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/real-world-analysis-of-cost-health
Publisher Site
http://dx.doi.org/10.2147/CEOR.S178649DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198880PMC
October 2018
7 Reads

A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK) lowering cardiovascular disease risk.

Clinicoecon Outcomes Res 2018 8;10:601-609. Epub 2018 Oct 8.

Hypertension Research Centre, University of Naples Federico II, Naples, Italy.

Context: Cardiovascular disease (CVD) costs the economy €210 billion per year in Europe. There is an association between low-density lipoprotein cholesterol (LDL-C) and CVD risk.

Objective: To evaluate the cost and effectiveness of LopiGLIK (LOPI) in lowering LDL-C and CVD risk. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/a-single-blind-multicenter-randomi
Publisher Site
http://dx.doi.org/10.2147/CEOR.S172838DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181120PMC
October 2018
7 Reads

The role of a best practice alert in the electronic medical record in reducing repetitive lab tests.

Clinicoecon Outcomes Res 2018 8;10:611-618. Epub 2018 Oct 8.

Department of Pathology, Immunology, & Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.

Background: The recommendations of the American Board of Internal Medicine Foundation's "Choosing Wisely" initiative recognize the importance of improving the appropriateness of testing behavior and reducing the number of duplicate laboratory tests.

Objective: To assess the effectiveness of an electronic medical record Best Practice Alert (BPA or "pop up") intervention aimed at reducing duplicate laboratory tests and hospital costs.

Design: Comparison of the number of duplicated laboratory tests performed on inpatients before and after the intervention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S167499DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181108PMC
October 2018
1 Read

Comparison of real-world clinical and economic outcomes between the ThermoCool SF and ThermoCool catheters in patients undergoing radiofrequency catheter ablation for atrial fibrillation.

Clinicoecon Outcomes Res 2018 4;10:587-599. Epub 2018 Oct 4.

Johnson & Johnson Medical Device Epidemiology, New Brunswick, NJ, USA,

Introduction: This study evaluated the real-world clinical and economic outcomes associated with the use of the ThermoCool Surround Flow (SF) and ThermoCool catheters in atrial fibrillation (AF) ablation.

Methods: Adults with AF who underwent catheter ablation between January 1, 2013, and December 31, 2016, in a hospital outpatient setting were identified from the Premier Healthcare Database. Using a search strategy of hospital-charge descriptors, patients were classified into two mutually exclusive groups: ThermoCool SF catheter and ThermoCool catheter. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/comparison-of-real-world-clinical-
Publisher Site
http://dx.doi.org/10.2147/CEOR.S180125DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181087PMC
October 2018
4 Reads

Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illness.

Clinicoecon Outcomes Res 2018 2;10:573-585. Epub 2018 Oct 2.

Health Economics and Outcomes Management, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.

Background: New digital technologies offer providers the promise of more accurately tracking patients' medication adherence. It is unclear, however, whether access to such information will affect provider treatment decisions in the real world.

Methods: Using prescriber-reported information on patient non-compliance from health insurance claims data between 2008 and 2014, we examined whether prescribers' knowledge of non-compliance was associated with different prescribing patterns for patients with serious mental illness (SMI). Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/does-knowledge-of-patient-non-comp
Publisher Site
http://dx.doi.org/10.2147/CEOR.S175877DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173173PMC
October 2018
16 Reads

Societal costs due to meningococcal disease: a national registry-based study.

Clinicoecon Outcomes Res 2018 2;10:563-572. Epub 2018 Oct 2.

Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.

Purpose: Limited detailed evidence exists on the societal costs of meningococcal disease. The objective of this study was to estimate the average 5-year societal cost of events attributable to meningococcal disease in Denmark.

Methods: The study was based on the nationwide Danish registries. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/societal-costs-due-to-meningococca
Publisher Site
http://dx.doi.org/10.2147/CEOR.S175835DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173181PMC
October 2018
14 Reads

Impact of a pharmacist-led diabetes management on outcomes, utilization, and cost.

Clinicoecon Outcomes Res 2018 24;10:551-562. Epub 2018 Sep 24.

Department of Epidemiology and Health Services Research, Geisinger, Danville, PA, USA,

Purpose: Pharmacist-led medication therapy disease management (MTDM) has shown improvement in clinical outcomes in patients with certain chronic diseases. However, only limited data demonstrating the impact on health care utilization and cost of care are available. This study seeks to evaluate the impact of a pharmacist-led MTDM program on clinical surrogate outcomes, care utilization, and cost of care among patients with diabetes mellitus. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/impact-of-a-pharmacist-led-diabete
Publisher Site
http://dx.doi.org/10.2147/CEOR.S174595DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161711PMC
September 2018
16 Reads

Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C.

Authors:
Katherine Heath

Clinicoecon Outcomes Res 2018 20;10:539-550. Epub 2018 Sep 20.

Mathematical Ecology Research Group, Department of Zoology, University of Oxford, Oxford OX1 3PS, UK,

Background: Cost-benefit analyses are crucial to inform treatment policies, particularly when the cost of patented drugs is very high. The cost of patented drugs is the limiting factor in hepatitis C treatment. However, hepatitis C drug costs are expected to fall following patent expiration, due to generic drug introduction. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/cost-effectiveness-analysis-of-tre
Publisher Site
http://dx.doi.org/10.2147/CEOR.S171248DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159796PMC
September 2018
2 Reads

Cost of acute cough in Italian children.

Clinicoecon Outcomes Res 2018 17;10:529-537. Epub 2018 Sep 17.

AdRes Health Economics and Outcome Research, Torino, Italy,

Objectives: Acute cough is the most common symptom among children in primary care, but the economic impact of cough episodes has never been investigated in Italian families.

Materials And Methods: A cross-sectional telephone survey was conducted on a representative sample of Italian families, randomly selected from general population. Collected data were analyzed to evaluate the economic impact of cough episodes according to, first, Italian Family Perspective and, second, National Health System Perspective (NHS-P). Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/cost-of-acute-cough-in-italian-chi
Publisher Site
http://dx.doi.org/10.2147/CEOR.S167813DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6147201PMC
September 2018
13 Reads

Propensity score matching comparison of laparoscopic versus open surgery for rectal cancer in a middle-income country: short-term outcomes and cost analysis.

Clinicoecon Outcomes Res 2018 12;10:521-527. Epub 2018 Sep 12.

Department of Anesthesia and Critical Care, University of São Paulo, Faculty of Medicine, São Paulo, Brazil,

Background: Laparoscopic surgery for rectal cancer is associated with improved postoperative outcomes compared to open surgery; however, economic studies have yielded contradictory results. The aim of this study was to compare the clinical and economic outcomes of laparoscopic versus open surgery for patients with rectal cancer.

Methods: Propensity score matching analysis was performed in a retrospective cohort of patients who underwent elective low anterior resection for rectal cancer treatment by laparoscopic and open surgery in a single Brazilian cancer center. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/propensity-score-matching-comparis
Publisher Site
http://dx.doi.org/10.2147/CEOR.S173718DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140693PMC
September 2018
17 Reads

Cost-effectiveness analysis of voriconazole, fluconazole, and amphotericin B for invasive fungal infections following allogeneic hematopoietic stem cell transplantation in Mexico.

Clinicoecon Outcomes Res 2018 6;10:511-520. Epub 2018 Sep 6.

Pfizer International Operations, Paris, Île-de-France, France,

Background: Patients receiving allogeneic hematopoietic stem cell transplantation (alloHSCT) are at high risk of invasive fungal infections (IFIs), which are associated with high mortality and economic burden. The cost-effectiveness of prophylaxis for the prevention of IFIs in alloHSCT recipients in Mexico has not yet been assessed.

Methods: This analysis modeled a hypothetical cohort of 1,000 patients to estimate costs and outcomes for patients receiving prophylaxis for IFIs following alloHSCT, from the perspective of institutional payers in Mexico. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S157642DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130275PMC
September 2018
7 Reads

Cost-consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS.

Clinicoecon Outcomes Res 2018 5;10:501-510. Epub 2018 Sep 5.

Market Access, GlaxoSmithKline, Tres Cantos, Madrid, Spain,

Objectives: The Salford Lung Study in Chronic Obstructive Pulmonary Disease (SLS COPD) is a 12-month, open-label randomized clinical trial comparing clinical effectiveness and safety of initiating once-daily fluticasone furoate/vilanterol (FF/VI) 92/22 mcg with continuing usual care (UC) in patients with COPD followed in primary care in the UK. The objective of this analysis is to estimate the economic impact of these results when applied to Spain.

Materials And Methods: An Excel-based cost-consequence model with a one-year time horizon was populated with SLS COPD results, adopting the Spanish National Health System (NHS) perspective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S169154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132231PMC
September 2018
2 Reads

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar.

Clinicoecon Outcomes Res 2018 3;10:493-500. Epub 2018 Sep 3.

Health Economics and Outcomes Research, Optum, Eden Prairie, MN, USA,

Background: Filgrastim and other granulocyte colony-stimulating factors are recommended to decrease febrile neutropenia (FN) incidence among patients with nonmyeloid cancers undergoing chemotherapy. Data comparing biosimilar filgrastim-sndz with reference filgrastim (filgrastim-ref) are limited outside of clinical trials in the US.

Objective: To compare the incidence of FN across chemotherapy cycles 1-6 between patients treated with filgrastim-sndz vs filgrastim-ref. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S168298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126503PMC
September 2018
5 Reads

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative.

Clinicoecon Outcomes Res 2018 30;10:477-491. Epub 2018 Aug 30.

S.A.V.E. S.r.l. Studi Analisi Valutazioni Economiche Health Economics & Outcomes Research - research center, Milan, Italy,

Objective: Secukinumab, a fully human monoclonal IgG1 antibody that selectively neutralizes the proinflammatory cytokine IL-17A, has been approved in Europe in 2015 for the treatment of adult patients with moderate-to-severe plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This analysis assessed the budget impact of introduction of secukinumab to the Italian market for all three indications from the perspective of the Italian National Health Service.

Materials And Methods: A cross-indication budget impact model was developed and included biologic-treated adult patients diagnosed with psoriasis, PsA, and AS. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/budget-impact-model-of-secukinumab
Publisher Site
http://dx.doi.org/10.2147/CEOR.S171560DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121773PMC
August 2018
9 Reads

Obesity in Germany and Italy: prevalence, comorbidities, and associations with patient outcomes.

Clinicoecon Outcomes Res 2018 24;10:457-475. Epub 2018 Aug 24.

Novo Nordisk, Plainsboro, NJ, USA.

Purpose: This study investigated the association between body mass index (BMI) and three comorbid conditions (type 2 diabetes [T2D], prediabetes, and hypertension) on humanistic and economic outcomes.

Patients And Methods: This retrospective observational study collected data from German (n=14286) and Italian (n=9433) respondents to the 2013 European Union National Health and Wellness Survey, a cross-sectional, nationally representative online survey of the general adult population. Respondents were grouped, based on their self-reported BMI, and stratified into three other comorbid conditions (T2D, prediabetes, and hypertension). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S157673DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113914PMC
August 2018
12 Reads

Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA.

Clinicoecon Outcomes Res 2018 16;10:443-456. Epub 2018 Aug 16.

Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA.

Objective: This study used a decision-analytic framework to assess the cost-effectiveness of brexpiprazole vs comparator branded therapies for reducing relapses and hospitalizations among adults with schizophrenia from a US payer perspective.

Methods: An economic model was developed to assess patients with stable schizophrenia initiating treatment with brexpiprazole (1-4 mg), cariprazine (1-6 mg), or lurasidone (40-80 mg) over a 1-year period. After 6 months, patients remained on treatment or discontinued due to relapse, adverse events, or other reasons. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/relapse-prevention-a-cost-effectiv
Publisher Site
http://dx.doi.org/10.2147/CEOR.S160252DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6101022PMC
August 2018
7 Reads

Cost of opioid medication abuse with and without tampering in the USA.

Clinicoecon Outcomes Res 2018 10;10:433-442. Epub 2018 Aug 10.

Statistical Research & Data Science Center, Pfizer Inc., New York, NY, USA.

Objective: To provide per-patient estimates of the economic burden for opioid medication abuse with and without tampering.

Patients And Methods: Adults in the US who participated in the 2010 and/or 2011 National Health and Wellness Survey were resurveyed to provide information on use and abuse of prescription opioids in the previous 3 months. Participants (N=20,885) were categorized as those who abused and tampered (n=107), abused without tampering (n=118), those who reported using of opioids as prescribed (n=981), and non-opioid controls (n=19,679). Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/cost-of-opioid-medication-abuse-wi
Publisher Site
http://dx.doi.org/10.2147/CEOR.S168145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089114PMC
August 2018
11 Reads

The burden of cystic fibrosis in the Medicaid population.

Clinicoecon Outcomes Res 2018 25;10:423-431. Epub 2018 Jul 25.

Division of Respiratory Diseases, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Purpose: To conduct an analysis describing clinical characteristics, pulmonary exacerbation (PEx) events, and health care resource utilization among Medicaid-insured patients with cystic fibrosis (CF).

Patients And Methods: A retrospective analysis of the Truven Health MarketScan Medicaid Multi-State administrative claims database (2010-2014) was undertaken. Patients aged ≥6 years with a CF diagnosis, continuously enrolled for 12 months, were identified. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/the-burden-of-cystic-fibrosis-in-t
Publisher Site
http://dx.doi.org/10.2147/CEOR.S162021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065469PMC
July 2018
21 Reads

Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes.

Clinicoecon Outcomes Res 2018 26;10:413-421. Epub 2018 Jul 26.

Department of Drug Sciences, University of Pavia, Pavia, Italy,

Background: Diabetes represents a relevant public health problem worldwide due to its increasing prevalence and socioeconomic burden. There is no doubt that tight glycemic control reduces the development of diabetic complications such as the long-term costs related to the disease. The aim of our model was to calculate total direct costs associated with the two treatments considered in DUAL VII study, and hence evaluate the potential economic benefits for the National Health System (NHS) deriving from the use of insulin degludec plus liraglutide (IDegLira) in a once-daily fixed combination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S169045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067612PMC
July 2018
12 Reads

Procedure costs associated with the use of Harmonic devices compared to conventional techniques in various surgeries: a systematic review and meta-analysis.

Clinicoecon Outcomes Res 2018 24;10:399-412. Epub 2018 Jul 24.

Ethicon Inc, Cincinnati, OH, USA.

Background: As compared to conventional techniques, recent meta-analyses have reported cost savings with Harmonic devices; however, only in thyroidectomy. Thus, the aim of this study was to evaluate the costs associated with Harmonic devices versus conventional techniques across a range of surgical procedures.

Methods: A systematic search of MEDLINE, EMBASE, and Cochrane Library was conducted from inception to October 01, 2016 without language restrictions to identify randomized controlled trials comparing Harmonic devices to conventional techniques and reporting procedure costs (operating time plus operating equipment/consumables/device costs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEOR.S164747DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063248PMC
July 2018
7 Reads

Impact of comorbidity on the risk and cost of hospitalization in HIV-infected patients: real-world data from Abruzzo Region.

Clinicoecon Outcomes Res 2018 23;10:389-398. Epub 2018 Jul 23.

Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy,

Background: Due to the success of antiretroviral therapy, human immunodeficiency virus (HIV) infection has been transformed into a lifelong condition. In Italy, little is known about the impact of comorbidities (CMs) on the risk of hospitalization and related costs for people who live with HIV (PWLHIV). The objective of the study was to quantify the risk of hospitalization and costs associated with CMs in an Italian cohort of PWLHIV. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/impact-of-comorbidity-on-the-risk-
Publisher Site
http://dx.doi.org/10.2147/CEOR.S162625DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061204PMC
July 2018
6 Reads